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Sarah Elizabeth Severance 
 
RISK OF LOWER EXTREMITY AMPUTATION REVISION IN PATIENTS  
WITH PERIPHERAL VASCULAR DISEASE ADJUSTING FOR  
A COMPETING RISK OF DEATH 
 
 Objectives: The aims of this study are to estimate the cumulative incidence of lower 
extremity amputation (LEA) revision and reamputation adjusting for a competing risk of death, 
estimate the one-year event-free mortality rates for patients with peripheral vascular disease 
undergoing LEA, and develop predictive models for LEA revision and reamputation adjusting for 
a competing risk of death. 
 Methods: This was a retrospective review of the prospectively collected Vascular 
Quality Initiative (VQI) registry between 2013 and 2018. Adults undergoing unilateral LEA were 
included. Demographics, comorbidities, medications, smoking status, history of vascular 
procedures and revascularization attempts, and procedure urgency were considered. Models to 
predict LEA revision and reamputation were developed using multivariable regression on the 
interval-censored competing risks data using semiparametric regression on the cumulative 
incidence function.  
 Results: The cumulative incidences of LEA revision and revision-free mortality within 
one year of index amputation are 14.9% and 15.5% respectively. Patient BMI, smoking status, 
aspirin use, history of revascularization, and level of planned LEA are significantly associated 
with the odds of LEA revision. Age, amputation urgency, dialysis, and level of planned LEA are 
associated with the one-year odds of revision-free mortality. A patient receiving an index above 
knee amputation (AKA) has 61% lower odds of LEA revision (p < 0.0001) but 51% higher odds 
of revision-free mortality following LEA (p < 0.0001). Previous revascularization procedures 
increase the odds of revision by 23% (p < 0.0001).  
 v 
 The cumulative incidences of reamputation and one-year reamputation-free mortality 
following LEA are 11.5% and 16.9% respectively. Urgency of the procedure, history of 
revascularization procedures, and level of planned LEA are statistically associated with the odds 
of reamputation when adjusting for the competing risk of death. Patients receiving index AKA 
have 62% lower odds of reamputation (p < 0.0001) compared to BKA. Dialysis is the strongest 
predictor of one-year mortality (OR 2.576, p < 0.0001).  
 Conclusions: Patients with appropriately managed PVD, which still progresses to 
amputation have higher odds of LEA revision and reamputation. Revision risk can be predicted 
and compared on the basis of patient factors and the planned index amputation.  
 
 
Giorgos Bakoyannis, PhD, Chair 
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INTRODUCTION 
 There are an estimated 185,000 limb amputations performed in the United States every 
year at a cost of more than $4 billion annually (1, 2). Estimates for the proportion of limb loss 
related to peripheral vascular disease (PVD) range from 38% to 82% (2-4). There has also been a 
positive trend noted in the number of these amputations performed for vascular disease (2). 
Lower extremity amputation (LEA) is a particularly morbid operation with the incidence of post-
operative wound complications reported as high as 10% following below knee amputation (BKA) 
and 7.2% following above knee amputation (AKA) (5, 6). The incidence of reamputation to a 
more proximal anatomic level due to failure of the initial LEA is estimated to be between 8% and 
26% depending on the study and the exact patient population considered (1, 7, 8).  
 Patient factors such as concomitant sepsis, emergent amputation, obesity, active tobacco 
use, preoperative functional status, insulin-dependent diabetes, and end stage renal disease 
(ESRD) are significant risk factors for amputation revision or reamputation following LEA (5, 6, 
9, 10).  Previous revascularization attempts have been shown to increase a patient’s risk of 
amputation revision but not the risk of reamputation to a more proximal anatomic level (11). The 
level of index LEA is also related to the risk of revision and reamputation. Patients who undergo 
a foot or ankle level amputation have a higher frequency of reamputation compared to patients 
who undergo a higher index amputation (1). In addition to the higher rate of wound 
complications, patients receiving an index BKA have significantly higher risk of subsequent 
hospital readmission compared to those receiving index AKA. On the contrary, patients receiving 
an index AKA have a higher mortality rate and worse functional outcomes (5, 8, 12, 13).   
 If the morbidity associated with LEA wasn’t enough, the all-cause mortality rate 
following LEA is astounding. In a 2017 meta-analysis of mortality following LEA, the composite 
one-year mortality rate was 47.9% (14). Diabetes, coronary artery disease, cerebrovascular 
disease, chronic renal disease, and non-ambulatory status were all common comorbid conditions 
in the patient population with PVD and were closely associated with death in this patient 
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population (14). The high population-specific mortality rate raises the issue of a competing risk of 
death when attempting to accurately estimate the incidence of LEA revision or reamputation. A 
competing risk can be defined as any alternative outcome of clinical significance, which may 
alter the probability of observing the event of interest (15, 16). In this case, it is reasonable to 
consider that some patients are likely to die of comorbid conditions before progressing to LEA 
revision or reamputation despite actually having wound complications or worsening underlying 
PVD which may have otherwise lead to reoperation had they survived long enough. An entirely 
separate group of patients will either be lost to follow-up or “censored” at the close of the study 
time. In other words, we hypothesized that by adjusting for a competing risk of death, we can 
differentiate between those who die and those who are lost to follow-up, and therefore, more 
accurately estimate the incidence of LEA revision or reamputation.    
 The first aim of this study was to estimate the cumulative incidence of amputation 
revision and reamputation in the first year following LEA adjusting for a competing risk of death. 
The second aim was to estimate the one-year event-free mortality rate following LEA in the 
patient population with PVD. The final aim of the study was to develop two separate prognostic 
models to preoperatively predict the one-year risk of LEA revision and reamputation also 
adjusting for a competing risk of death.  
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METHODS 
Study Design 
 This was a retrospective analysis of the prospectively collected Vascular Quality 
Initiative (VQI) registry maintained by the Society for Vascular Surgery - Patient Safety 
Organization (SVS-PSO). The VQI represents a collaborative effort of more than 500 centers 
across the United States who voluntarily contribute patient and procedure details (17). 
Participating centers are required to provide details for all procedures performed. Clinical data 
managers and professionals at each center enter data regarding initial procedures and follow-up 
information using patient medical charts and uniform variable definitions provided by the VQI 
data dictionary. Data are audited for completeness and accuracy annually using comparison with 
claims data (17). Mortality data are obtained from a combination of medical charts and the Social 
Security Death Index (SSDI). The maximum number of days survived following a procedure is 
defined by either the SSDI-confirmed date of death of the patient or the last known follow-up 
date in the medical records and VQI.  
 The VQI Amputation Module was queried from January 2013 to September 2018 for 
adult patients over the age of 18 years with PVD who underwent unilateral LEA. Patients 
undergoing bilateral LEA, defined as either part of the same operative procedure or contralateral 
amputation within 30 days of index LEA, and those undergoing a planned staged amputation 
were excluded from the study. LEA revision was defined as any return to the operating room for 
wound management or reoperation related to the index LEA. Reamputation was defined as 
reoperation with LEA to a higher defined anatomical level. For patients undergoing multiple 
revisions of the same index LEA, only the first revision was considered, and for patients 
undergoing contralateral LEA more than 30 days after the index LEA, only the first index LEA 
was considered in order to avoid the statistical issue of repeated measures on the same individual.   
 Patient demographics, body mass index (BMI), medical comorbidities (diabetes, coronary 
artery disease, congestive heart failure, chronic obstructive pulmonary disease, ESRD, dialysis 
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requirement, and hypertension), pre-operative smoking status, pre-operative use of aspirin, other 
antiplatelet medications, anticoagulants, beta-blockers, statins, and ACE-inhibitors, and history of 
previous vascular surgery procedures were considered. These variables were dichotomized into 
binary indicators of a comorbidity or regular medication use. Any previous amputation, arterial 
bypass, carotid stenting or endarterectomy, or aneurysm repair were noted. Patients were defined 
as having had an ipsilateral revascularization procedure if they reported having a history of inflow 
arterial bypass or endovascular stenting or lower extremity arterial bypass or stenting to the same 
leg subsequently requiring amputation. Given that the known date of last contact or death for each 
patient is constant within the database, the time between index LEA and revision or reamputation 
was determined using comparison of the number of days survived post-procedure for each 
operation. For example, if a patient was known to survive for 30 days after index LEA but only 
10 days after revision, the time between LEA and revision was defined as 20 days and considered 
accurate to within a 24-hour period.  
 Given the de-identification of the data, this work is exempt from approval by the Indiana 
University Institutional Review Board. The SVS-PSO National Research Advisory Committee 
approved the proposal for this project.  
Statistical Analysis 
 Patients were first grouped based on whether or not they required any LEA revision or 
reamputation within one year of index LEA. Demographic information, disease characteristics, 
comorbidity information, procedure details, and outcomes were calculated as raw descriptive 
statistics and incidences for the entire patient population. Two separate prognostic models were 
then pursued to predict any LEA revision (Model 1) and reamputation (Model 2). Each patient 
was defined as experiencing the first of either revision/reamputation or death within 365 days of 
index LEA. Death was considered a mutually exclusive competing risk as observation of death 
precludes observation of amputation revision or reamputation. Patients were considered lost to 
follow-up or right-censored at the minimum of either 365 days or their last known follow-up visit 
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time if they had neither a recorded revision/reamputation nor a confirmed date of death within the 
registry (Equation 1).  
 
𝐶!"#$% ! = 0 = 𝑅𝑖𝑔ℎ𝑡 𝐶𝑒𝑛𝑠𝑜𝑟𝑒𝑑1 = 𝑅𝑒𝑣𝑖𝑠𝑖𝑜𝑛              2 = 𝐷𝑒𝑎𝑡ℎ                        𝑎𝑛𝑑        𝐶!"#$% ! = 0 = 𝑅𝑖𝑔ℎ𝑡 𝐶𝑒𝑛𝑠𝑜𝑟𝑒𝑑1 = 𝑅𝑒𝑎𝑚𝑝𝑢𝑡𝑎𝑡𝑖𝑜𝑛  2 = 𝐷𝑒𝑎𝑡ℎ                                             
[Equation 1] 
where CModel 1 and CModel 2 represent the event indicators for Model 1 and Model 2 respectively. 
 For patients with complete records and a Social Security Number reported to the VQI, the 
time from index LEA to revision or reamputation could be determined to within a 24 hour period. 
However, for patients without the aid of the SSDI to determine the number of days survived after 
index LEA, the day of revision or reamputation was not precisely known and could only be 
determined to within a 60-day window. Therefore, all data on timing of revision or reamputation 
were considered interval-censored in order to minimize the bias introduced by measurement 
error. The cause-specific cumulative incidence function (CIF) is of most interest given the study 
goal of prognostication and can be shown to be as follows for the situation including two 
competing risks in Equation 2 (18, 19).  
 
𝐹! 𝑡 = Pr 𝑇 ≤ 𝑡,  𝐶 = 𝑗 =  𝜆! 𝑢 exp − 𝜆! 𝑤 𝑑𝑤!!!!!! 𝑑𝑢!! , 𝑗 = 1, 2 
[Equation 2] 
 
where λj (u) is the cause-specific hazard function and T is the failure time for the specific cause of 
failure, C. Regression analysis on the CIF using the traditional semiparametric proportional 
subdistribution hazards model (Fine-Gray Model) does not account for interval-censored data. 
Parametric likelihood approaches were avoided in order to avoid imposing strict assumptions for 
the possible causes of failure (20). Multivariable regression on the interval-censored competing 
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risks data was performed using semiparametric regression on the CIF in which each baseline 
“risk” function for the jth failure cause indicator is estimated non-parametrically using a B-spline 
based sieve maximum likelihood approach (21).  This approach does not impose distributional 
assumptions on the CIFs. The overall model estimated was a semiparametric transformation 
model using the logit link function called the proportional odds model and is given by the model 
equation (Equation 3) below.  
 𝑙𝑜𝑔𝑖𝑡 𝐹! 𝑡;𝑍, θ! = 𝜙! 𝑡 +  𝛽!!𝑍 
[Equation 3] 
where βj is the vector of parameter estimates and Z is the patient-specific covariate vector of 
interest. This implies that given a set of covariates, the cause-specific CIF for a specific 
individual at any time point, t, can be calculated using Equation 4 as follows.  
 
𝐹! 𝑡;𝑍,𝜙! ,𝛽! =  exp[𝜙! 𝑡 +  𝛽!!𝑍]1 +  exp[𝜙! 𝑡 +  𝛽!!𝑍] 
[Equation 4] 
 The baseline “risk” function, ϕj (t), is considered an infinite dimensional parameter as it 
can take on an infinite number of values over the continuous variable for time. This leads to a 
difficult and extremely computationally burdensome process to attempt maximization of the 
likelihood function. This can be remedied using the B-spline approach in order to maximize the 
likelihood over a sieve, which is a sequence of finite-dimensional parameter spaces that 
approximates the infinite-dimensional parameter space of ϕ (22). The B-spline can be thought of 
as a complex polynomial with the number of internal knots and order of the polynomial defined 
as Nj and mj respectively. It was used to non-parametrically estimate the baseline risk of LEA 
revision and reamputation without consideration of covariates as shown in Equation 5 where γj 
represent the unknown control points of the polynomial of the B-spline to be estimated (21, 22).  
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Θ!,! = 𝜙!: 𝜙! 𝑡 =  𝛾!,!𝐵!,!! 𝑡!!!!!!!! , 𝑡 ∈ 𝑎, 𝑏 ,𝛾! ∈  ℝ!!!!! , 𝛾!,! < ⋯ <  𝛾!,!!!!!  
[Equation 5] 
 For the interval-censored data with the event time bounded by the lower bound, V, and 
the upper time bound, U, the likelihood function consists of the portion contributed by those 
patients experiencing either amputation revision or reamputation within the interval [V, U] as well 
as the portion contributed by those who are right censored and lost to follow-up (21). Maximizing 
the likelihood function shown below (Equation 6) using the B-spline approach then leads to 
consistent and asymptotically normally distributed estimators. These estimators can then easily be 
used for further inference regarding amputation revision or reamputation (21). It should also be 
noted that maximization and determination of the cause-specific CIF must be done under the 
restriction that the sum of all cause-specific CIF functions at the maximum follow up time cannot 
exceed one (21). This leads to a constrained maximization problem.  
 
𝐿 𝜃,𝐷 ∝   𝐹! 𝑈!;  𝑍! , 𝜃! − 𝐹! 𝑉!;  𝑍! , 𝜃! !!"  !!!! 1 − 𝐹! 𝑉!;  𝑍! , 𝜃!
!
!!!
!!!!!
!!!   𝜃! = (𝜙! ,𝛽!!)′ 
 
[Equation 6]  
where δij is the indicator that the ith patient experienced the 𝑗th cause of failure. 
 Considering the pre-operatively available patient variables listed above, model selection 
was done on the basis of a pseudo-Akaike Information Criterion (pseudo-AIC) calculated as 
shown (Equation 7) considering a penalty for the number of parameter coefficients estimated for 
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each possible model. While it is certainly possible that other covariates may show an association 
with LEA revision or reamputation if included, only those that added to the model fit and 
predictive value without contributing undue complexity to the model were included. Additionally, 
keeping a relatively small number of predictors is more practical for clinical use of the prediction 
model. 
 𝑃𝑠𝑒𝑢𝑑𝑜 𝐴𝐼𝐶 =  −2 ∗ log 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 + 3 ∗ (# 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑) 
[Equation 7] 
The final models were those with the best predictive value as evidenced by the lowest pseudo 
AIC value. They were then run using 50 bootstrapped repetitions in order to estimate the variance 
of the parameter estimates and allow for calculation of confidence intervals and statistical 
inference. This model selection procedure is preferable over traditional variable selection 
approaches, such as backwards selection, as it does not utilize hypothesis testing, unlike the 
traditional approaches, and, therefore, does not lead to an abuse of type I error due to multiple 
comparisons. Also, it has been proven mathematically to lead to consistent model selection in 
simpler statistical models such as linear regression models (23). Statistical significance was 
defined as a Type I Error rate (α) < 0.05. The regression analysis was accomplished using the 
“intccr” package available in R version 3.5.3 (24). Data management and descriptive statistics 
were accomplished using SAS 9,4 (Cary, NC).  
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RESULTS 
 Out of the 12,068 total entries in the VQI registry Amputation Module, 8,156 individual 
patients with a single qualifying LEA were identified and included in the study. Index LEA level 
was transmetatarsal amputation (TMA) (20%), BKA (43%), AKA (34%), and other (3%). Of 
these, 885 (10.9%) were noted to have undergone any amputation revision, and 600 of those 
required reamputation to a higher anatomic level within one year of follow-up (Figure 1). The 
raw one-year mortality rate in the patient population was 1,140 deaths/8,156 patients (14%) 
(Figure 1). The most common conversion was BKA to AKA (n = 282) followed by TMA to BKA 
(n = 223) and TMA directly to AKA (n = 50).  In the total included patient population, the mean 
age was 65.3 years, 2,164 (26.6%) were active smokers at the time of index LEA, 5,613 (68.9%) 
had diabetes, and 1,496 (18.4%) were currently receiving dialysis (Table 1). The most common 
previous revascularization procedure to the ipsilateral leg was extremity percutaneous vascular 
intervention (PVI) in 15.2% (n = 1,239) of patients followed by extremity arterial bypass in 
10.4% (n = 851). Prior extremity PVI was noted in 20.9% (n = 185) of patients undergoing LEA 
revision and in 21.8% (n = 131) of patients who required reamputation to a higher level. Full 
details of patient demographics, comorbidities, and history can be found in Table 1.  
 The most common indications for index LEA were ischemic tissue loss in 4,044 (49.6%) 
patients and uncontrolled infection in 2,564 (31.4%) patients. Less than 10% of index LEAs (n = 
760) were considered emergent. Only 29.8% (n = 2,427) of patients were discharged directly to 
home following hospitalization for their index LEA while 68% (n = 5,215) of patients required 
discharge to either a rehabilitation or skilled nursing facility (Table 2). The median maximum 
follow-up time for all patients included in the study was 384 days (IQR 306-509). Procedure and 
discharge details can be seen in full in Table 2.  
Model 1- Any LEA Revision  
 When the baseline “risk” is estimated, the cumulative incidence of LEA revision at one-
year follow-up from index LEA was 14.9% while the cumulative incidence of revision-free death 
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was 15.5% (Figure 2a). The model to predict LEA revision (Model 1) includes the patient 
variables age, gender, BMI, urgency of amputation, smoking status, ESRD requiring dialysis, 
preoperative aspirin use, history of ipsilateral revascularization procedures, and the anatomic 
level of the planned index LEA. The model demonstrates that, of these, BMI, smoking status, 
preoperative aspirin use, history of ipsilateral vascular procedures, and level of the planned 
amputation are all statistically significantly associated with odds of LEA revision within one year 
of index LEA. Modeled simultaneously, patient age, amputation urgency, dialysis, and level of 
the planned amputation are all statistically significantly associated with the odds of revision-free 
death. The indication for index LEA, race, and other comorbidities, including diabetes, did not 
contribute adequately to the predictive value of the model and were excluded. The details of the 
final Model 1 selected can be seen in Table 3a. It should be noted that odds ratios (OR) provided 
represent the increase or decrease in odds of revision or death for a one-unit increase in the 
variable of interest. When a 10 kg/m2 difference in patient BMI is considered, a patient with a 
BMI of 35 kg/m2 has a 17% lower odds of revision (p = 0.0008) compared to an otherwise 
equivalent patient with a BMI of 25 kg/m2. A more proximal anatomic level of index LEA is 
protective against LEA revision but predictive of revision-free mortality within one year of index 
LEA. A patient receiving an index AKA has 61% lower odds (p < 0.0001) of LEA revision but 
51% higher odds (p < 0.0001) of revision-free mortality within one year compared to a patient 
who receives an index BKA (Table 3a). Patients who have had their PVD previously medically 
managed with aspirin or undergone revascularization procedures but have still progressed to 
index LEA have 33% (p = 0.0011) and 23% (p < 0.0001) higher odds of LEA revision within one 
year respectively when compared to counterparts without a history of these interventions (Table 
3a). Additionally, revascularization procedures are additive. A patient with a history of any two 
ipsilateral revascularization procedures has an OR of 1.52 (95% CI 1.39- 1.66) indicating an 
additional 28.7% increase in the odds of LEA revision compared to a patient with a history of 
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only one revascularization procedure. The most dramatic predictor of revision-free mortality is 
ESRD requiring dialysis (OR 2.818, p < 0.0001).   
Model 2- Reamputation  
 When only reamputation to a higher level was considered the event of interest, the 
baseline cumulative incidence of reamputation at one-year follow up was 11.5% while the 
cumulative incidence of reamputation-free death was 16.9% (Figure 2b). The details of the final 
Model 2 selected can be seen in Table 3b. The model to predict reamputation to a more proximal 
anatomic level (Model 2) includes the same covariates listed in Model 1. Index LEA level, 
urgency of the procedure, and history of prior revascularization procedures are statistically 
significantly associated with the risk of reamputation. Age, index LEA level, urgency of the 
procedure, ESRD requiring dialysis, and history of prior revascularization procedures are 
associated with the risk of reamputation-free mortality within one year of index LEA. A 10-year 
increase in age increases the odds of mortality by 43% (p < 0.0001). When considering only 
major reamputation, patient BMI is no longer significantly associated with reamputation (p = 
0.0968) or mortality (p = 0.5808). Patients receiving an index AKA have 62% lower odds of 
reamputation (p < 0.0001) and 53% higher odds of reamputation-free mortality (p < 0.0001) 
within one year of index LEA compared to patients undergoing index BKA. Patients undergoing 
an elective index LEA have 29% lower odds of reamputation (p = 0.0045) but 39% higher odds 
of mortality (p = 0.0033) compared to those that require emergent index LEA (Table 3b). Similar 
to Model 1, the most dramatic predictor of reamputation-free mortality remains ESRD requiring 
dialysis (OR 2.576, p < 0.0001).  
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DISCUSSION 
 Our data demonstrate a cumulative incidence of 14.9% for LEA revision, 11.5% for 
reamputation, and 15.5% to 16.9% for event-free mortality in the year following LEA. The 
estimated cumulative incidences of revision and reamputation are comparable to current 
literature. There is a very wide range of estimates reported likely due at least in part to the 
relatively small sample size of many available studies. Kelly et.al. demonstrated that between 
2000 and 2012, the proportion of patients requiring LEA reamputation to a higher level has 
decreased substantially from 11.5% to 7.2% (25). A cohort study by Schmiegelow et.al. reported 
that of 180 amputations, 21.6% required reamputation within 90 days of index LEA (26). When 
follow-up is extended to 3 years, Kono et.al. found a 49.1% incidence of reamputation among 
116 patients with PVD (10). In a larger study by Dillingham et.al. in 2005, 3565 patients with 
PVD who underwent LEA were included, and 26% ultimately required an additional amputation 
procedure within one year following index LEA (1). More closely related to our chosen analysis, 
in 2014 Rosen et.al. completed a study of 188 patients who underwent LEA for ischemic or 
infectious reasons (27). The authors used survival analysis with a Cox proportional hazards model 
to assess mortality following BKA vs. AKA and were able to support the finding that mortality is 
higher following AKA. Interestingly, they were also able to demonstrate that the bulk of 
reoperations following index LEA occur within the first year post-operatively (27). This is in 
direct agreement with the findings of our study which also suggest that early LEA revision and 
reamputation are much more common early than late with a steep upslope in the cumulative 
incidences between 0 and 100 days following index LEA.  
 Our raw overall mortality rate estimate of 14% is relatively low when compared to rates 
previously reported in the literature. A meta-analysis by Stern et.al. looking specifically at 
mortality included 16 separate studies reporting a range of mortality rates from 9.1% to 53% with 
a composite mortality rate calculated to be 47.9% one year after index LEA (14). It is important 
to keep in mind that our reported event-free mortality rate does not include those patients who 
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died within one year of index LEA after requiring revision or reamputation. Patients are not 
considered further after requiring revision. Thus, caution should be used when comparing our 
event-free mortality rate of 15.5% to 16.9% with overall mortality rates reported in the literature.  
 Insulin-dependent diabetes, ESRD, BMI, resistant bacterial infections, gangrene present 
at the time of index LEA, history of prior revascularization attempts, active tobacco use, and need 
for emergency operation are significant risk factors for reoperation in the existing literature (1, 6, 
9-11, 27). Both Model 1 and Model 2 detailed by our analysis are generally in agreement with 
these findings and support the importance of patient BMI, ESRD requiring dialysis, smoking, and 
previous revascularization attempts. O’Brien et.al. demonstrated an adjusted 215% higher odds of 
early amputation failure within 30 days of index LEA when the procedure is done emergently. 
This is in direct comparison to the 20-30% increased odds of revision or reamputation for an 
emergent versus elective procedure found in our study (6). Wu et.al. calculated an OR of 3.85 for 
reamputation from BKA to AKA associated with ESRD (9). The statistically insignificant p-
values in our models (Tables 3a and 3b) should not be interpreted to say that ESRD is not a risk 
factor for revision. Rather, it is meant to be interpreted as one simultaneous model suggesting that 
ESRD requiring dialysis increases the risk of mortality so dramatically that it precludes the 
observance of any increased risk of LEA revision or reamputation related to ESRD.  
 Studies have consistently supported a lower risk of amputation failure for higher 
anatomic levels of index LEA (1, 6, 10, 27). When comparing BKA and AKA, Rosen et.al. noted 
reamputation to a higher level in 15.8% and 3.6% of patients respectively (p = 0.018) (27). 
Dillingham et.al. noted the highest percentage of progression to a higher level of amputation 
among those undergoing foot amputation (1). Looking specifically at anatomic levels within foot 
amputation, Kono et.al. were able to demonstrate higher proportions of reamputation for patients 
undergoing metatarsal and toe amputations compared to those undergoing midfoot or hindfoot 
amputations (10).   
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 Finally, our models both demonstrate a statistically significant association between 
previous revascularization attempts, whether PVI or open bypass, and the odds of LEA revision 
or reamputation (p < 0.0001 and p = 0.0003 respectively). In Model 2, previous ipsilateral 
revascularization procedures were also statistically significantly associated with one-year 
reamputation-free mortality (p = 0.0001). A previous study by Barnes et.al. matched patients 
based on comorbidities and demographics and found that those undergoing amputation after a 
previous revascularization attempt were significantly more likely to require revision surgery (p = 
0.027) but not reamputation (p = 0.341). They also found no increased risk of mortality (p = 
0.782) based on Kaplan-Meier survival analysis (11). The association between previous 
revascularization procedures and mortality in our results may be simply due to a tendency to offer 
revascularization to patients with fewer comorbidities and less severe PVD overall.  
 While the preceding discussion demonstrates the compatibility of our results with 
existing literature, the crux of this analysis rests on the consideration of death as a competing risk 
to revision and reamputation. The importance of this consideration is outlined here. In 2016, 
Serizawa et. al. specifically investigated the mortality and amputation-free survival of patients on 
dialysis undergoing major LEA using a Kaplan-Meier analysis (28). The group was able to 
demonstrate a 56% survival rate and 39% amputation-free survival rate following the patient’s 
first major LEA, but while these results illustrate the dramatic mortality rate in this subpopulation 
of patients with PVD, it did not directly control for the competing risk of death (28).  In 
traditional survival analysis using a Kaplan-Meier estimate to calculate the cumulative incidence 
of the event of interest, patients who die and those who are lost to follow-up are both considered 
right-censored despite being quite different in reality (15). Patients considered right-censored are 
included in the total “at risk” population for revision or reamputation for the full yearlong 
duration of the study. This is appropriate for those patients lost to follow-up and presumed to be 
alive and thus truly at risk of reoperation, but it is not appropriate for patients who have died. 
Grouping these patients together in the Kaplan-Meier analysis has been shown to lead to 
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overestimation of the incidence of the event of interest (15). The accuracy of our models to 
predict the incidence of LEA revision or reamputation is improved by considering the cause-
specific CIF which accounts for the competing risk of death (16). The estimates provided by the 
competing risk analysis represent the probability of LEA revision or reamputation given that a 
patient is free of revision and has survived up to the time point of interest (15, 16).  
 For instance, when the traditional Kaplan-Meier survival analysis is done for LEA 
revision in our dataset simply considering those who die to be right censored at the time of death, 
the incidence of revision is 15.9% compared to the 14.9% estimated using the competing risk 
analysis on interval-censored data. While comparing 15.9% to 14.9% (a 6.3% bias or 
overestimation) does not appear dramatic, we must consider also that this overestimation is 
sensitive to the mortality rate in the population. In a simulation by Berry et.al. arguing in favor of 
competing risk analysis for elderly patients, they demonstrated that this bias increase from 9.5% 
to 47.6% as mortality increased from 10% to 85% (15). It follows also that as the number of 
patients remaining alive and able to experience the event of interest decreases over time, this bias 
towards overestimation will become more pronounced as patients are followed out further in 
time. In our patient population with PVD, the fact that the revision-free mortality rate of 15.5% to 
16.9% and interest in only one-year post-amputation outcomes produces a measurable bias 
suggests that the competing risk analysis is imperative for evaluation of any long-term outcomes 
or complications in these patients.  
 Previous literature has supported the use of a competing risk analysis in both aging 
patient populations as well as those with high risk of premature death (15, 18, 19). A study by 
Jacqmin-Gadda et.al. to predict the 10-year risk of dementia in elderly patients developed a 
predictive model adjusting for the competing risk of death before diagnosis of dementia (29). The 
authors were able to demonstrate the improved predictive value of their model based on ROC 
analysis for a patient population shown to have a raw 10-year mortality rate of 36%. Assessing a 
patient population clinically more similar to the patient population of interest in our study, in 
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2012, Grams et.al. established the importance of considering a competing risk analysis for 
patients with ESRD and peripheral vascular disease. The authors compared analyses done without 
and then with the competing risk adjustment and found a 66% to 51% drop and 51% to 29% drop 
for the incidence of ESRD and death prior to diagnosis with ESRD, respectively when death is 
considered a competing risk (30).  The staggering mortality rates following LEA undeniably 
place patients with PVD requiring amputation into the high-risk category for premature death. 
These findings are also in agreement with the results of our study demonstrating more than a 
200% increased odds of mortality for patients with PVD on dialysis before ever progressing to 
LEA revision or reamputation (Tables 3a and 3b).  
 Interval censoring is a common phenomenon in medicine as medical providers are 
frequently unable to pinpoint an exact time of disease onset. Two options traditionally used to 
deal with this uncertainty using single imputation include right imputation, which assumes the 
onset occurred at the time of the most recent medical encounter and midpoint imputation, which 
assumes the onset of disease occurred at the midpoint between medical encounters (31). Both of 
these options introduce measurement error which in turn leads to biased regression parameter 
estimates (31). A third option for dealing with interval censoring in medical studies is to use 
multiple imputation, but this method has been shown to lead to potential bias due to 
misspecification of the imputation model used to impute the missing failure time data (32, 33).  
By considering the full interval during which we are certain the failure or censoring occurred, we 
avoid these biases in estimation of the CIF and regression parameter estimates in our models.  
 Despite the use of a prospectively collected and maintained registry, this study is limited 
by the retrospective nature of the analysis. It is also subject to the limitations of the VQI database 
including the lack of several desirable data points. For instance, the VQI database provides 
information on whether a patient has diabetes and what treatment regimen they are on to manage 
their diabetes, but it does not include preoperative or post-operative hemoglobin A1C values to 
indicate adequacy of blood glucose management. Including diabetes as a control variable in our 
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models did not add to their predictive value despite previous studies demonstrating worse 
outcomes following LEA for patients with diabetes (1, 10). Additionally, with 50.3% of 
preoperative ankle-brachial index (ABI) values missing for the included patient population in the 
VQI registry, the decision was made to exclude this variable from model consideration despite its 
potential clinical importance. It is unclear how much of the missing data for ABI is related to 
reporting and how much is due to an actual lack of testing. Finally, while the VQI provides a 
large sample size, the registry is composed of voluntarily participating centers only and may not 
be perfectly representative of the greater patient population with PVD.  
 The next step for this project is to build a user-friendly tool to allow clinical 
implementation of these models in practice. By including only variables that should be readily 
available to the surgeon preoperatively, our vision is to incorporate the model into an interface 
capable of quickly calculating the cumulative incidences based on user entry of covariate values. 
We also plan to pursue validation of the predictive ability of our models using a new data set, 
which will allow determination of the sensitivity and specificity of the models.  
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CONCLUSIONS 
 Our models provide a means to predict any LEA revision (Model 1) or reamputation to a 
higher anatomic level while adjusting for and simultaneously modeling the cumulative incidence 
of death within one year following index LEA. Patients who have been appropriately medically 
managed with aspirin and have had previous revascularization procedures as well as those 
actively smoking have higher odds of LEA revision or reamputation. Adding the planned level of 
index LEA into the model not only improves the predictive value but also will allow clinicians to 
compare and contrast the revision and reamputation risk based on the index operation offered to 
the patient. Our hope is that these models may help guide preoperative conversations and shared 
decision-making when planning the level of index LEA. 
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APPENDICES 
Appendix A- Tables  
Table 1: Patient characteristics, preoperative health status, and history of vascular procedures for the total patient population and the subgroups 
that required any amputation revision or reamputation to a more proximal anatomic level within one year of initial lower extremity amputation. 
 Total Population 
(n = 8156) 
No Revision Group 
(n = 7271) 
Revision Group 
(n = 885) 
Reamputation Group 
(n = 600) 
Age (years), mean (SD) 65.3 (13.0) 63.4 (12.4) 63.4 (13.1) 64.5 (12.1) 
Gender, n (%) male 5282 (64.8) 4672 (64.3) 610 (68.9) 407 (67.8) 
Race, n (%) 
     White 
     Black 
     Other 
 
4770 (58.5) 
2862 (35.1) 
524 (6.4) 
 
4248 (58.4) 
2541 (34.9) 
482 (6.6) 
 
522 (59.0) 
321 (36.3) 
42 (4.7) 
 
356 (59.3) 
217 (36.1) 
27 (4.6) 
Primary Insurer, n (%) 
     Medicare 
     Medicaid 
     Private 
     Military 
     None 
 
4648 (57.0) 
883 (10.8) 
2213 (27.2) 
88 (1.1) 
305 (3.7) 
 
4179 (57.5) 
764 (10.5) 
1965 (27.0) 
79 (1.1) 
278 (3.8) 
 
469 (53.0) 
119 (13.5) 
248 (28.0) 
9 (1.0) 
40 (4.5) 
 
325 (54.2) 
75 (12.5) 
167 (27.8) 
8 (1.3) 
25 (4.2) 
BMI (kg/m2) 27.9 (7.7) 27.8 (7.3) 27.9 (7.7) 27.7 (7.4) 
Pre-op Smoking Status, n (%) active 
smoker 
2164 (26.6) 2905 (40.0) 352 (39.8) 180 (30.1) 
Pre-op Comorbidities, n (%) 
     Hypertension 
     Diabetes 
     CAD 
     CHF 
     COPD 
     Dialysis 
 
7199 (88.3) 
5613 (68.9) 
2545 (31.2) 
2307 (28.3) 
1902  (23.3) 
1496 (18.4) 
 
6400 (88.0) 
4975 (68.4) 
2268 (31.2) 
2097 (28.8) 
1725 (23.7) 
1322 (18.2) 
 
799 (90.4) 
638 (72.1) 
277 (31.3) 
210 (23.7) 
177 (20.0) 
174 (19.7) 
 
546 (91.2) 
432 (72.1) 
192 (32.1) 
146 (24.5) 
125 (20.9) 
129 (21.5) 
Pre-op Hemoglobin (gm/dL) 9.9 (2.2) 10.1 (2.0) 9.9 (2.2) 10.1 (2.0) 
Pre-op Ambulation, n (%) 
     Ambulatory 
 
3263 (40.2) 
 
2852 (39.2) 
 
411 (46.7) 
 
264 (44.2) 
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     Assistance 
     Wheelchair 
2846 (35.0) 
1627 (20.0) 
2513 (34.6) 
1504 (20.7) 
333 (37.8) 
123 (14.0) 
238 (39.9) 
87 (14.6) 
Pre-op ASA Class, n (%) 
     I 
     II 
     III 
     IV 
     V 
 
6 (0.1) 
154 (1.9) 
4747 (58.4) 
3170 (39.0) 
46 (0.57) 
 
5 (0.07) 
136 (1.9) 
4188 (57.6) 
2868 (39.4) 
44 (0.6) 
 
1 (0.1) 
18 (2.0) 
559 (63.4) 
302 (34.2) 
2 (0.2) 
 
0 (0) 
14 (2.3) 
378 (63.2) 
204 (34.1) 
2 (0.3) 
Pre-op Medications, n (%) 
     Aspirin 
     P2Y12 Antagonist 
     Statin 
     Beta Blocker 
     ACE/ARB 
     Anticoagulant 
 
4915 (60.3) 
2271 (27.8) 
5263 (64.6) 
4592 (56.3) 
3299 (40.5) 
1806 (22.1) 
 
4325 (59.5) 
1966 (27.0) 
4666 (64.2) 
4078 (56.1) 
2896 (39.8) 
1610 (22.1) 
 
590 (66.7) 
305 (34.5) 
597 (67.5) 
514 (58.1) 
403 (45.6 
196 (22.1) 
 
393 (65.5) 
215 (35.9) 
404 (67.3) 
346 (57.8) 
270 (45.0) 
143 (24.0) 
Previous Vascular Procedures, n (%) 
Arterial Bypass 
CEA/CAS 
Aneurysm Repair 
PVI 
Any Amputation 
 
2184 (26.8) 
352 (4.3) 
157 (1.9) 
3089 (37.9) 
3795 (46.6) 
 
1902 (26.1) 
304 (4.2) 
145 (2.0) 
2671 (36.7) 
3359 (46.2) 
 
282 (31.9) 
48 (5.4) 
12 (1.4) 
418 (47.2) 
436 (49.3) 
 
205 (34.2) 
30 (5.0) 
6 (1.0) 
292 (48.7) 
288 (48.1) 
Previous Ipsilateral Vascular 
Procedures, n (%) 
Inflow Bypass 
Inflow PVI 
Extremity Bypass 
Extremity PVI 
Amputation 
 
 
272 (3.3) 
396 (4.8) 
851 (10.4) 
1239 (15.2) 
2937 (36.0) 
 
 
244 (3.4) 
347 (4.8) 
731 (10.1) 
1054 (14.5) 
2588 (35.6) 
 
 
28 (3.2) 
49 (5.5) 
120 (13.6) 
185 (20.9) 
349 (39.4) 
 
 
19 (3.2) 
32 (5.3) 
86 (14.3) 
131 (21.8) 
228 (38.0) 
ASA = preoperative anesthesia physical status classification 
ACE = angiotensin converting enzyme inhibitor 
ARB = angiotensin receptor blocker 
CEA = carotid endarterectomy 
CAS = carotid artery stent 
PVI = percutaneous vascular intervention (any non-cardiac endovascular intervention) 
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Table 2: Details of initial amputation, discharge from the hospital, and follow-up for the total patient population and the subgroups that required 
amputation revision or reamputation to a more proximal anatomic level within one year of initial lower extremity amputation. 
 Total Population 
(n = 8156) 
No Revision Group 
(n = 7271) 
Revision Group 
(n = 885) 
Reamputation Group  
(n = 600) 
Urgency, n (%) 
     Elective  
     Urgent  
     Emergent 
 
5418 (66.6) 
1958 (24.1) 
760 (9.3) 
 
4830 (66.4) 
1737 (23.9) 
687 (9.4) 
 
588 (66.7) 
221 (25.1) 
73 (8.3) 
 
412 (690) 
140 (23.5) 
45 (7.5)  
Indication for Initial  
Amputation, n (%)  
     Ischemic Rest Pain 
     Ischemic Tissue Loss 
     Acute Ischemia  
     Uncontrolled Infection 
     Neuropathic Tissue Loss 
     Other 
 
 
479 (5.9) 
4044 (49.6) 
688 (8.4) 
2564 (31.4) 
232 (2.8) 
149 (1.8) 
 
 
411 (5.7) 
3598 (49.5) 
613 (8.4) 
2303 (31.7) 
207 (2.8) 
139 (1.9) 
 
 
68 (7.7) 
446 (50.4) 
75 (8.5) 
261 (29.5) 
25 (2.8) 
10 (1.1) 
 
 
45 (7.5) 
338 (56.3) 
49 (8.2) 
148 (24.7) 
15 (2.5) 
5 (0.8) 
Transfusion required, n (%) 3091 (37.9) 2798 (38.5) 293 (33.1) 194 (32.6) 
EBL (mL), mean (SD) 145.8 (177.9) 106.2 (123.2) 150.6 (182.8) 100.6 (110.8) 
Discharge Ambulation, n (%)  
     Ambulatory 
     Assistance 
     Wheelchair  
     Bedridden 
 
325 (4.1) 
3167 (39.6) 
3634 (45.4) 
882 (11.0) 
 
267 (3.7) 
2740 (37.7) 
3285 (45.2) 
838 (11.5) 
 
58 (6.6) 
427 (48.6) 
349 (39.8) 
44 (5.0) 
 
35 (5.9) 
283 (47.5) 
250 (42.0) 
28 (4.7) 
Discharge Medications, n (%)  
     Aspirin 
     P2Y12 Antagonist 
     Statin 
     Beta Blocker 
     ACE/ARB 
     Anticoagulant 
 
5352 (66.4) 
2455 (30.1) 
5468 (67.8) 
4734 (58.7) 
3079 (38.2) 
2048 (25.1) 
 
4693 (64.5) 
2126 (29.2) 
4839 (66.6) 
4192 (57.7) 
2711 (37.3) 
1815 (25.0) 
 
659 (74.6) 
329 (37.2) 
629 (71.2) 
542 (61.4) 
368 (41.7) 
233 (26.3) 
 
443 (73.8) 
227 (37.9) 
429 (71.5) 
361 (60.2) 
246 (41.0) 
172 (28.7) 
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Discharge Status, n (%)  
     Home 
     Rehab Facility  
     Nursing Facility 
     Other Hospital 
     Dead (in hospital) 
 
2427 (29.8) 
3110 (38.2) 
2105 (25.8) 
225 (2.8) 
8 (0.1) 
 
2118 (29.1) 
2759 (37.9) 
1913 (26.3) 
201 (2.8) 
272 (3.7) 
 
309 (35.0) 
351 (39.8) 
192 (21.7) 
24 (2.7) 
5 (0.6) 
 
197 (32.9) 
239 (40.0) 
145 (24.3) 
12 (2.0) 
3 (0.5) 
Median Max Follow-Up, median (IQR) 384 (306-509) 365 (296-475) 387 (308-514) 369 (289-477) 
 
Table 3a: Model 1 showing the odds ratios (OR), 95% Confidence Intervals (CI) for the OR, and p-values for the risks of lower extremity 
amputation revision and death as competing risks modeled using a proportional odds model on interval-censored competing risks data.   
 Revision Revision-Free Death 
 OR 95% CI p-value OR 95% CI p-value 
Female Gender 0.950 (0.803- 1.123) 0.5454 1.075 (0.939- 1.231) 0.296 
Age (years)  0.996 (0.990- 1.002) 0.1959 1.037 (1.029- 1.044) <0.0001 
BMI (kg/m2) 0.982 (0.971- 0.992) 0.0008 0.993 (0.982- 1.005) 0.265 
Amputation Level 
     AKA vs. BKA 
     AKA vs. TMA 
     BKA vs. TMA  
 
0.398 
0.100 
0.251 
 
(0.371- 0.428) 
(0.084- 0.120) 
(0.226- 0.280) 
<0.0001  
1.509 
2.797 
1.854 
 
(1.379- 1.651) 
(2.235- 3.501) 
(1.620- 2.121) 
<0.0001 
Urgency 
     Elective vs. Urgent 
     Elective vs. Emergent 
     Urgent vs. Emergent 
 
0.895 
0.800 
0.895 
 
(0.790- 1.013) 
(0.625- 1.026) 
(0.790- 1.013) 
0.0786  
1.171 
1.371 
1.171 
 
(1.037- 1.322) 
(1.075- 1.748) 
(1.037- 1.322) 
0.0110 
Smoking  1.269 (1.058- 1.523) 0.0104 0.975 (0.815- 1.166) 0.781 
Dialysis 1.047 (0.871- 1.260) 0.6222 2.818 (2.343- 3.390) <0.0001 
Pre-op Aspirin  1.331 (1.121- 1.582) 0.0011 0.925 (0.802- 1.067) 0.286 
History of Vascular 
Procedures (ipsilateral) 
1.232 (1.124- 1.351) <0.0001 0.933 (0.853- 1.021) 0.1310 
*Bolded p-values are statistically significant at the 0.05 level   
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Table 3b: Model 2 showing the odds ratios OR, 95% CI for the OR, and p-values for the risks of reamputation to a more proximal anatomic level 
and death as competing risks also modeled using a proportional odds model on interval-censored competing risks data.   
 Reamputation Reamputation-Free Death 
 OR 95% CI p-value OR 95% CI p-value 
Female Gender 0.957 (0.810- 1.130) 0.6012 1.046 (0.918- 1.191) 0.5015 
Age (years)  0.999 (0.990- 1.008) 0.8578 1.032 (1.025- 1.040) <0.0001 
BMI (kg/m2) 0.989 (0.977- 1.002) 0.0968 0.997 (0.986- 1.008) 0.5808 
Amputation Level 
     AKA vs. BKA 
     AKA vs. TMA 
     BKA vs. TMA  
 
0.385 
0.092 
0.238 
 
(0.350- 0.423) 
(0.072- 0.116) 
(0.207- 0.275) 
<0.0001  
1.532 
2.907 
1.897 
 
(1.386- 1.694) 
(2.262- 3.735) 
(1.632- 2.205) 
<0.0001 
Urgency 
     Elective vs. Urgent 
     Elective vs. Emergent 
     Urgent vs. Emergent 
 
0.844 
0.712 
0.844 
 
(0.751- 0.949) 
(0.564- 0.900) 
(0.751- 0.949) 
0.0045  
1.178 
1.387 
1.178 
 
(1.056- 1.314) 
(1.115- 1.726) 
1.056- 1.314) 
0.0033 
Smoking  1.147 (0.956- 1.377) 0.1406 0.915 (0.778- 1.078) 0.2881 
Dialysis 1.011 (0.810- 1.261) 0.9261 2.576 (2.124- 3.123) <0.0001 
Pre-op Aspirin 1.160 (0.979- 1.376) 0.0866 0.907 (0.797- 1.032) 0.1391 
History of Vascular 
Procedures (ipsilateral) 
1.161 (1.071- 1.259) 0.0003 0.861 (0.799- 0.928) 0.0001 
*Bolded p-values are statistically significant at the 0.05 level  
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Appendix B- Figures 
 
 
Figure 1: Decision tree demonstrating the inclusion and exclusion criteria for the study, the final 
number of patients included, and the number of patients experiencing the events of interest.  
 
  
	 25 
a.  
b.  
 
Figure 2: Non-parametrically estimated baseline “risk” of amputation revision adjusting for a 
competing risk of death (top) and reamputation to a more proximal anatomic level also adjusting 
for a competing risk of death (bottom) within the first year following index lower extremity 
amputation. Note that the estimated mortality in both instances is event-free mortality and NOT 
overall mortality.  
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